Sébastien Gagneux, Professor, PhD

Function(s)
Head of Department

Organisational Entity

Sébastien Gagneux is Professor of Infection Biology and Head of the Department of Medical Parasitology and Infection Biology at the Swiss Tropical and Public Health Institute (Swiss TPH)/University of Basel. After receiving his PhD from the University of Basel, he worked as a postdoctoral fellow at Stanford University and at the Institute for Systems Biology in Seattle, USA. He then spent three years as a Program Leader at the MRC National Institute for Medical Research in London, UK before joining Swiss TPH. His research focuses on the ecology and evolution of Mycobacterium tuberculosis with a particular focus on antimicrobial resistance.

 

Profile

Sébastien Gagneux is Professor of Infection Biology and Head of Department at the Swiss Tropical and Public Health Institute (Swiss TPH) / University of Basel. After receiving his PhD from the University of Basel, he worked as a postdoctoral fellow at Stanford University and at the Institute for Systems Biology in Seattle, USA. He then started his own laboratory at the MRC National Institute for Medical Research in London, UK, before joining Swiss TPH. His research focuses on the ecology and evolution of Mycobacterium tuberculosis with a particular focus on antimicrobial resistance.

Latest Publications

All Publications

Hall M.B et al. Evaluation of nanopore sequencing for Mycobacterium tuberculosis drug susceptibility testing and outbreak investigation: a genomic analysis. Lancet Microbe. 2023;4(2):e84-e92. DOI: 10.1016/S2666-5247(22)00301-9

Cox H et al. Whole genome sequencing has the potential to improve treatment for rifampicin-resistant tuberculosis in high burden settings: a retrospective cohort study. J Clin Microbiol. 2022;60(3):e0236221. DOI: 10.1128/jcm.02362-21

Hiza H et al. CD38 expression by antigen-specific CD4 t cells is significantly restored 5 months after treatment initiation independently of sputum bacterial load at the time of tuberculosis diagnosis. Front Med. 2022;9:821776. DOI: 10.3389/fmed.2022.821776

Maghradze N et al. Developing customized stepwise MIRU-VNTR typing for tuberculosis surveillance in Georgia. PLoS One. 2022;17(3):e0264472. DOI: 10.1371/journal.pone.0264472

Merker M et al. Transcontinental spread and evolution of Mycobacterium tuberculosis W148 European/Russian clade toward extensively drug resistant tuberculosis. Nat Commun. 2022;13:5105. DOI: 10.1038/s41467-022-32455-1

Otchere I.D et al. Analysis of drug resistance among difficult-to-treat tuberculosis patients in Ghana identifies several pre-XDR TB cases. Front Microbiol. 2022;13:1069292. DOI: 10.3389/fmicb.2022.1069292

Van Rie A et al. Balancing access to BPaLM regimens and risk of resistance. Lancet Infect Dis. 2022;S1473-3099(22):00543-6. DOI: 10.1016/S1473-3099(22)00543-6

Vera-Cabrera L et al. Mycobacterium leprae infection in a wild nine-banded armadillo, Nuevo León, Mexico. Emerg Infect Dis. 2022;28(3):747-749. DOI: 10.3201/eid2803.211295

Xu Z.M et al. Using population-specific add-on polymorphisms to improve genotype imputation in underrepresented populations. PLoS Comput Biol. 2022;18(1):e1009628. DOI: 10.1371/journal.pcbi.1009628

Alagna R et al. Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice?. Eur Respir J. 2021;58:2100959. DOI: 10.1183/13993003.00959-2021